AKT1 and neoplasm: Most significantly, in an in vivo study, ARQ 092 and ARQ 751 showed strong anti-tumor activity against a homologous AKT1 mutant (AKT1-E17K) endometrial cancer patient-derived xenograft (PDX) model.